ReviewJournal of molecular neuroscience : MN2003
From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.
Review in Journal of molecular neuroscience : MN, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01056965 (A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide), which is not on this map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies
Who cites it
36 citing papers in PubMed.
- Activity-dependent neuroprotective protein (ADNP) derived peptide NAP prevents musculoskeletal abnormalities in ovariectomized mice.Frontiers in neuroscience · 2026Article
- Editorial: Neuropeptide GPCRs in neuroendocrinology, Volume II.Frontiers in endocrinology · 2023Article
- PACAP and NAP: Effect of Two Functionally Related Peptides in Diabetic Retinopathy.Journal of molecular neuroscience : MN · 2021Review
- Review
- Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Against Cognitive Decline in Neurodegenerative Diseases.Frontiers in cellular neuroscience · 2020Article
- Developmental Phenotype of the Rare Case of DJ Caused by a Unique ADNP Gene De Novo Mutation.Journal of molecular neuroscience : MN · 2019Article
- NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies.PloS one · 2019Article
- Antidepressant effect of recombinant NT4-NAP/AAV on social isolated mice through intranasal route.Oncotarget · 2017Article
- Nap Interferes with Hypoxia-Inducible Factors and VEGF Expression in Retina of Diabetic Rats.Journal of molecular neuroscience : MN · 2017Article
- The mitotic tensegrity guardian tau protects mammary epithelia from katanin-like1-induced aneuploidy.Oncotarget · 2016Article
- Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress.Brain research · 2016Review
- The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer's Disease.Proteomes · 2016Article
- Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure.Acta pharmacologica Sinica · 2015Review
- NAP reduces murine microvascular endothelial cells proliferation induced by hyperglycemia.Journal of molecular neuroscience : MN · 2014Article
- The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins.Molecular psychiatry · 2014Article
- Review
- Emerging neuropeptide targets in inflammation: NPY and VIP.American journal of physiology. Gastrointestinal and liver physiology · 2013Review
- Neurotrophic Peptides: Potential Drugs for Treatment of Amyotrophic Lateral Sclerosis and Alzheimer's disease.Open journal of neuroscience · 2013Article
- Protective effects of vasoactive intestinal peptide (VIP) in ischemic retinal degeneration.Journal of molecular neuroscience : MN · 2012Article
- Involvement of PACAP/ADNP signaling in the resistance to cell death in malignant peripheral nerve sheath tumor (MPNST) cells.Journal of molecular neuroscience : MN · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accelerated neuronal death brings about cognitive as well as motor and other dysfunctions. A major neuropeptide, vasoactive intestinal peptide (VIP), has been shown to be neuroprotective. However, VIP-based drug design is hampered by the instability of the peptide and its limited bioavailability. Two independent approaches were thus taken to exploit VIP as a lead drug candidate: (1) Potent neuroprotective lipophilic analogs of VIP were synthesized, e.g. [stearyl-norleucine-17] VIP (SNV); and (2) potent neuroprotective peptide derivatives were identified that mimic the activity of VIP-responsive neuroprotective glial proteins. VIP provides neuronal defense by inducing the synthesis and secretion of neuroprotective proteins from astrocytes; activity-dependent neuroprotective protein (ADNP) was discovered as such glial cell mediator of VIP- and SNV-induced neuroprotection. In subsequent studies, an eight-amino-acid peptide, NAP, was identified as the smallest active element of ADNP exhibiting potent neuroprotective activities. This paper summarizes the biological effects of SNV and NAP and further reports advances in NAP studies toward clinical development. An original finding described here shows that NAP, while protecting neurons, demonstrated no apparent effect on cell division in a multiplicity of cell lines, strengthening the notion that NAP is a specific neuroprotective drug candidate.
Indexed as
Identifiers
14501014What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.